Replies to post #439864 on NorthWest Biotherapeutics Inc (NWBO)

[VikingInvest]

Love how these new supposedly longs come in with a lot of misinformation in their first post. There's way too many misstatements in your post to comment on, but:

NWBO does not keep delaying. They have never given a date. There might be posters on here who are throwing out dates, but that's just guessing.

[pqr]

It Is: I have a whole lot of money tied up and I feel just fine, thanks for your personal concern which I don’t really understand any point of your question.

[Madame Brie]

Didn’t u just created your account 26 January 2022? Lol a good laugh of the day.

[Gasd]

I have been reading this board as well for the last 6 years or so... I am a long investor (started Q2 2016 after I sold my CLDX investment following some arguments with LaCoursière - remember him - ?) and I feel exactly like you do. After all these years and failed expectations, I start to doubt. Very few remember what we have faced in the last 5 years... I do. I have strongly supported the management, though. But they take too much time to execute. And time is money... I just start to be tired of all this.

Beside of manufacturing, I find strange that all recent good news are not PR's by the company. But who knows, maybe all the backstage discussions with BP and regulators are true ? So many posters over the years have created calendars with timeline of important events which ended... nowhere.

I guess we are all due to get a positive sign from the Co that is not related to CDMO manufacturing and more debt financing...

[bas2020]

Doesn't it worry you guys even a little that NWBO always finds ways to keep delaying?

The only thing I question are supposed long-time investors who decide to create an alias in recent days just to vent. Very much question the "sincerity" of such posts.

One should only consider the time since data lock... and there are good reasons for the delay.

[dennisdave]

The ONLY reason why I have NOT sold my NWBO shares given the present situation is described precisely by SOS in his last blog

Top management may or may not be still blinded to the data at this point in time, but it is almost certain that at least one member of management or an outside member of the statistical analysis team is unblinded. If the trial had failed, they would have been obligated to inform top management who would then have the legal obligation to inform investors that the trial had failed to reach its primary endpoints as outlined on the UK website. Failure to announce this material information publicly would have been securities fraud. This is strongly suggestive to me that the trial did achieve statistical significance for mOS in both ndGBM and rGBM patients.